Your market access model may be quietly eroding more value than you realize. In today’s environment, up to 50% of commercial value is lost due to market access challenges.
As policy pressures from the IRA, evolving MFN frameworks, and sweeping PBM reform reshape the landscape—compressing both the pricing ceiling and the commercial window for branded drugs—the cost of fragmented execution has shifted from inefficiency to structural business risk. What was once manageable complexity has devolved to slowing decisions, weakening accountability, and widespread launch underperformance.
Current fragmented operating models cannot withstand these pressures and fail to deliver the speed, coordination, and outcomes required in this new reality.
This must‑read perspective examines how fragmented market access strategies are driving commercial risk, and how biopharma leaders can achieve better results through an integrated, accountable model.
Author
John brings over 30 of pharmaceutical, biotechnology, device, and diagnostic industry leadership experience in commercialization, market access, reimbursement, HEOR, government affairs, sales, and marketing. John has an extensive background in life sciences management consulting focused…